1. Home
  2. OMH vs RNTX Comparison

OMH vs RNTX Comparison

Compare OMH & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ohmyhome Limited

OMH

Ohmyhome Limited

N/A

Current Price

$1.25

Market Cap

28.7M

Sector

Finance

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.25

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OMH
RNTX
Founded
2015
2001
Country
Singapore
United States
Employees
N/A
11
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.7M
30.0M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
OMH
RNTX
Price
$1.25
$1.25
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
23.9K
98.8K
Earning Date
11-28-2025
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$28.40
N/A
Revenue Next Year
$23.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$1.02
52 Week High
$4.33
$2.22

Technical Indicators

Market Signals
Indicator
OMH
RNTX
Relative Strength Index (RSI) 48.78 44.91
Support Level $1.03 $1.07
Resistance Level $1.37 $1.30
Average True Range (ATR) 0.09 0.13
MACD 0.00 -0.01
Stochastic Oscillator 60.98 20.00

Price Performance

Historical Comparison
OMH
RNTX

About OMH Ohmyhome Limited

Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: